Neil Lyons

Neil Lyons Email and Phone Number

Chief Financial Officer @ Lazurite
Colorado Springs, CO, US
Neil Lyons's Location
Colorado Springs, Colorado, United States, United States
About Neil Lyons

Strategic finance executive/CPA focused on increasing shareholder value through corporate growth. Industry experience includes: biotechnology / life sciences, telecommunications (wireline and satellite), information technology, and federal contracting. Influential in corporate environments ranging from start-up, less than a dozen employees; to mid-sized, 1500 employees; to large (Verizon).Specialties: Corporate strategy, financing (raised over $160M in equity and debt capital and $19M in U.S. Federal contracts for biotechnology companies, with career-to-date, transaction deal sheet exceeding $1B), financial reporting (SEC/NASDAQ compliance), corporate governance (SOX, FCPA), M&A, information systems/business process re-engineering and personnel management.Community: Previously active with Technology Council of Maryland including: Mentor with the TCM's Venture Mentoring Services.

Neil Lyons's Current Company Details
Lazurite

Lazurite

View
Chief Financial Officer
Colorado Springs, CO, US
Neil Lyons Work Experience Details
  • Lazurite
    Chief Financial Officer
    Lazurite
    Colorado Springs, Co, Us
  • Lazurite
    Chief Financial Officer
    Lazurite Jun 2023 - Present
    Cleveland, Ohio, Us
    Lazurite is commercializing a first-in-class wireless arthroscope for surgical applications "ArthroFree,". Surgery untethered.
  • Ironbridge Consulting
    Founder
    Ironbridge Consulting Aug 2021 - Present
    Advisory and fractional CFO services to emerging life science companies, leveraging 15+ years as a serial life science CFO to public and private entities. Additionally, well-skilled in federal contracting through many years of industry experience in the Washington D. C. area.
  • Ampel Biosolutions
    Chief Financial Officer
    Ampel Biosolutions Aug 2021 - Present
    Charlottesville, Virginia, Us
    AMPEL delivers precision medicine solutions to patients using RNA analytics, bioinformatics, and machine learning/AI to evaluate disease status, identify molecular pathways and predict drug options. While initially focused on immunology, the AMPEL Genomic Platform (AGP®) is applicable to a host of disease indications.
  • Maryland Tech Council
    Member Of The Maryland Tech Council
    Maryland Tech Council 2009 - 2022
    Frederick , Maryland, Us
    At the Maryland Tech Council, we believe in saving lives, securing our nation and improving the quality of life through innovation.We support our member companies who are driving innovation through advocacy, education, workforce development, cost savings and connecting entrepreneurial minds.
  • American Gene Technologies International, Inc
    Executive Vice President & Chief Financial Officer
    American Gene Technologies International, Inc Apr 2017 - Aug 2021
    Rockville, Maryland, Us
    AGT is a gene and cell therapy company with a proprietary gene-delivery platform for rapid development of cell and gene therapies to cure infectious diseases, cancers, and inherited disorders. AGT has three programs under development with its lead program for HIV patients in clinical development. The other two pre-clinical programs include a unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors, and a proprietary treatment for Phenylketonuria (PKU), a debilitating inherited disease. AGT's treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA.Website: www.americangene.com
  • Panacela Labs, Inc.
    Board Member
    Panacela Labs, Inc. Apr 2014 - Apr 2017
    Panacela Labs, Inc. is a joint venture founded in 2011 by Cleveland BioLabs, Inc. (NASDAQ:CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs, and Open Joint Stock Company “Rusnano,” in conjunction with Roswell Park Cancer Institute, Children’s Cancer Institute Australia and The Cleveland Clinic Foundation. Panacela is 66.77% owned by CBLI.Panacela's lead development program is Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand, a secretory non-glycosylated version of entolimod. Mobilan is in clinical development as an immunotherapy for cancer.Websites:Panacela Labs, Inc.: www.panacelalabs.comRusnano: www.rusnano.comCBLI: www.cbiolabs.com
  • Cleveland Biolabs, Inc.
    Executive Vice President & Chief Financial Officer
    Cleveland Biolabs, Inc. Sep 2011 - Apr 2017
    Buffalo, Ny, Us
    CBLI (www.cbiolabs.com) is a multi-national, clinical-stage, drug development, company focused on oncology with a radiation countermeasure in pivotal development. CBLI is headquartered in Buffalo, New York with operations in Moscow, Russia. • Raised $68 million in debt and equity financing through several transactions with Ladenburg Thalmann, Oppenheimer & Co., Cantor Fitzgerald, Hercules Technology Growth Capital, et.al, including a recent $25 million equity investment from a single individual at a 21% premium to the trailing 60 day VWAP.• Executed $7 million in subsidiary recapitalizations/divestitures.• Captured $15.8 million of U.S. government development contracts/grants.• Attracted analysts to launch coverage and managed investor relations/external communications.• Regularly represents the company through road shows and investor presentations.• Transitioned CBLI from research to clinical development, downsizing employees from 60+ to less than 20, adding biotech industry talent to the Board and executive staff.• Sets corporate strategy in conjunction with the Board, and fellow executives regarding clinical development, financing, partnering/licensing, executive and staff benefits, etc. • Implemented the Deltek accounting software package to facilitate Federal contract compliance. Re-engineered financial processes, including hiring a new team to manage an international consolidation (two US and three Russian entities.)
  • Regenerx Biopharmaceuticals, Inc.
    Chief Financial Officer
    Regenerx Biopharmaceuticals, Inc. Apr 2005 - Aug 2011
    Leveraging third-party vendors, RegeneRx’s lean staff of 10 managed multiple clinical development programs, and 3 drug formulations, including CNS, cardiovascular, internal organ repair; ophthalmic; and, epidermal wounds. (www.regenerx.com), (OTC:RGRX)• Raised $37 million in several transactions including a fully-marketed follow-on offering on Form S-1, with Piper Jaffray, Royal Bank of Canada, et.al., along with several privately negotiated transactions with existing shareholders. • Established an $11 million equity line-of-credit facility with Lincoln Park Capital. • Captured a $3 million development contract with the National Institutes of Health. • Developed detailed, Excel-based, financial models to manage/forecast clinical trial activity, licensing opportunities, financial reporting and cash flows.• One of three executive team members who negotiate all external contracts, including those for drug development and CRO/CMO services.• Manage all SEC/Sox compliance. Implemented a suite of employee benefits.
  • Ironbridge Consulting
    Founder
    Ironbridge Consulting Jun 2003 - Apr 2005
    Provided executive consulting services, as a sole proprietor, for example:• BearingPoint - revenue recognition.• Initial Sox implementation for Hanger Orthopedic, and Martek Biosciences Corporation.
  • Alcatel/Skybridge L.P.
    V.P. Finance (Functional Cfo)
    Alcatel/Skybridge L.P. Oct 1998 - Jun 2003
    Espoo, Southern Finland, Fi
    Alcatel, a French leader in telecommunications created SkyBridge, in 1997. SkyBridge was to develop new low earth orbit (“LEO”), broadband satellite technology, build and deploy the satellites, and operate a global telecommunications company. Other investors included: Loral, Boeing, Toshiba, EMS, Qualcomm, Marsh, et. al. • Evaluated multiple acquisition targets and JV opportunities. Executed due diligence for, a $200+million JV between Alcatel, SES Global and Gilat. • Secured capital through road shows, drafted PPMs, negotiated investment terms. Results: Equity grew from approximately $100 million to $400 million (Alcatel increased their investment from $50 million to $200 million), Partners grew from 8 to 20, secured $700 million in debt financing, arranged $7.5 million in project financing with ABN AMRO – Sydney, Australia. Given the depressed financial condition of the telecom industry and Alcatel specifically, Alcatel closed SkyBridge’s US operations in 2003.
  • Bell Atlantic, Now Verizon
    Director Strategic Financial Systems
    Bell Atlantic, Now Verizon Apr 1996 - Oct 1998
    Recruited by a former colleague to lead business process re-engineering activities needed to implement PeopleSoft financial and human resource applications. $13 billion in revenue. • Influenced company-wide buy-in to the project, enlisted volunteers and led a 30-person, cross-functional, matrixed, team to define the strategy within four months, two months ahead of schedule.• Influenced buy-in throughout the organization, securing $70m in funding. Business case review committee: “If this is not the best, it is the second best business case we have ever seen.”• Placed several systems into operation, including a critical BA/NYNEX merger platform.
  • Wang Federal, Inc. (Formerly Hfsi, A Subsidiary Of Honeywell)
    Division Controller
    Wang Federal, Inc. (Formerly Hfsi, A Subsidiary Of Honeywell) Sep 1990 - Apr 1996
    Wang Federal was a $300 million, international, CAS-compliant, Federal systems integrator, including product sales, maintenance, consulting, build-to-order, and training services. Originally hired as the Controller reporting to a Division CFO, assumed the CFO’s responsibilities after a merger with Wang reporting to both the Division President and Corporate CFO. • Influenced a redefinition of market strategy, resulting in an initial $9m contract.• Implemented Oracle financial applications, sophisticated on-line analytical processing (“OLAP”) tools, and a custom-built time reporting system. Results: (1) a 60% finance staff reduction from 100 employees to 40, (2) the “first ever” insights into profitability by business unit, contract, customer and product, (3) an improvement in the closing process from 5 days to 3, and (4) new financial metrics.• Improved receivable days outstanding by 40%, over $10 million, through coordinating a cross-functional, six-sigma styled team.• Due diligence and post-merger integration for a $150 million transaction with Wang.• Managed a $25 million asset-backed line of credit.• Insured CAS/FAR compliance, and proper revenue recognition in accordance with GAAP, for bundled software & services.
  • Deloitte
    Senior Audit Manager
    Deloitte May 1979 - Sep 1990
    Worldwide, Oo
    Performed audit and Federal contracting advisory services for ERC a NYSE company, Computer Sciences Corporation, OAO, and other Federal contractors, approximately 50% of total practice. Performed due diligence, drafted SEC documents, and negotiated disclosures for: • Dart Drug Stores, a $300 million mid-Atlantic drug store chain – $160 million troubled debt restructuring. Investment bankers: Oppenheimer. • Hechinger, a $1 billion hardware retailer – $60 million acquisition of Home Quarters.• Presidential Airways, a $200 million regional passenger air carrier - $75 million IPO. Two acquisitions of regional air carriers. Secondary debt and equity offerings, bringing total capitalization to $250 million. Investment bankers: Alex. Brown.

Neil Lyons Skills

Mergers And Acquisitions Start Ups Due Diligence Strategy Financial Modeling Financial Reporting Finance Investments Mergers Leadership Acquisition Integration Management Strategic Planning Venture Capital Valuation Investor Relations Executive Management Financial Analysis Corporate Development Acquisitions Program Management Ipo Sarbanes Oxley Act Management Consulting Corporate Governance Corporate Finance Auditing Cross Functional Team Leadership Consulting Accounting Financial Accounting Sales Corporate Law Sec Financial Reporting Legal Compliance Internal Audit Legal Documents

Neil Lyons Education Details

  • Florida Southern College
    Florida Southern College
    Accounting

Frequently Asked Questions about Neil Lyons

What company does Neil Lyons work for?

Neil Lyons works for Lazurite

What is Neil Lyons's role at the current company?

Neil Lyons's current role is Chief Financial Officer.

What is Neil Lyons's email address?

Neil Lyons's email address is nl****@****ene.com

What is Neil Lyons's direct phone number?

Neil Lyons's direct phone number is +171684*****

What schools did Neil Lyons attend?

Neil Lyons attended Florida Southern College.

What are some of Neil Lyons's interests?

Neil Lyons has interest in Landscape Architecture, Cooking, Skiing, Cycling, Antiques.

What skills is Neil Lyons known for?

Neil Lyons has skills like Mergers And Acquisitions, Start Ups, Due Diligence, Strategy, Financial Modeling, Financial Reporting, Finance, Investments, Mergers, Leadership, Acquisition Integration, Management.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.